Major international lung cancer clinical trial launched

The NCIC Clinical Trials Group (NCIC CTG) in Kingston, Ontario, has developed and will lead an international clinical trial of a new class of cancer drug aimed at curing lung cancer in patients who have had surgery and chemotherapy for disease confined to the lung. The NCIC CTG is funded by the Canadian Cancer Society. The trial will impact lung cancer patients following standard treatment. The new drug is one of a new class of pharmaceuticals that helps the body’s immune system recognize and attack cancer. Drugs in this class have already been approved for use in patients with malignant melanoma. Read more here.